These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21341561)

  • 1. Alfuzosin induced thrombocytopenia after treatment for benign prostatic hyperplasia.
    Güner S; Mutlu B; Güner E; Taşçi AI
    Arch Ital Urol Androl; 2010 Dec; 82(4):195-7. PubMed ID: 21341561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.
    Schulman CC; De Sy W; Vandendris M; Tomas M; Santoni JP
    Acta Urol Belg; 1994 Dec; 62(4):15-21. PubMed ID: 7540794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-1 adrenergic antagonists induced severe rhinitis in patients with benign prostatic hyperplasia.
    Shahar E; Nassar L; Kedem E; Hassoun G
    Curr Drug Saf; 2014; 9(2):159-60. PubMed ID: 24861992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective masked comparison of intraoperative floppy iris syndrome severity with tamsulosin versus alfuzosin.
    Chang DF; Campbell JR; Colin J; Schweitzer C;
    Ophthalmology; 2014 Apr; 121(4):829-34. PubMed ID: 24314842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
    Kuritzky L; Rosenberg MT; Sadovsky R
    Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy of alfuzosin (dalfaz) in patients with benign prostatic hyperplasia].
    Tkachuk VN; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (2):38-40. PubMed ID: 9577703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Resnick MI; Roehrborn CG
    Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
    McVary KT
    J Urol; 2006 Jan; 175(1):35-42. PubMed ID: 16406865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A clinical trial of the treatment of patients with benign prostatic hyperplasia using the alpha 1-adrenoblocker alfuzosin].
    Lopatkin NA; Perepanova TS
    Urol Nefrol (Mosk); 1997; (5):14-6. PubMed ID: 9412005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study.
    Chung JH; Lee JY; Kang DH; Jo JK; Lee JW; Lee SH; Lee KS; Kim TH; Han JH; Lee SW
    Int J Clin Pract; 2013 Sep; 67(9):870-5. PubMed ID: 23952466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
    Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
    Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand.
    Leungwattanakij S; Watanachote D; Noppakulsatit P; Petchpaibuol T; Choeypunt N; Tongbai T; Wanamkang T; Lojanapiwat B; Permpongkosol S; Tantiwong A; Pripatnanont C; Akarasakul D; Kongwiwatanakul S; Chotikawanich E
    J Sex Med; 2010 Sep; 7(9):3115-26. PubMed ID: 20233288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
    Mazo EB; Matushevskiĭ IA; Nikitin IuIu
    Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of alfuzosin 10 mg once daily on quality of life in Tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia].
    Ben Rhouma S; H'sairi M; Adbi H; Binous MY; Nouira Y; Ben Raies N; Mosbah AT; Horchani A
    Tunis Med; 2015 Mar; 93(3):164-9. PubMed ID: 26367405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible visual loss caused by combination therapy of alfuzosin and finasteride in a patient with uveitic glaucoma.
    Lee JW; Lee HJ
    Cutan Ocul Toxicol; 2013 Jun; 32(2):182-4. PubMed ID: 23094797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alfuzosin-induced acute liver injury.
    Kim SY; Kim BH; Dong SH; Kim HJ; Chang YW; Chang R; Kim YW
    Korean J Hepatol; 2007 Sep; 13(3):414-8. PubMed ID: 17898558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.